Friday, 16 October 2026European Markets

NHOA Stock Over 31% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of nhoa (cac 40: nhoa.pa) jumped by a staggering 31.18% in 10 sessions from €3.4 to €4.46 at 11:06 est on wednesday, following the last session's downward trend. cac 40 is sliding 0.36% to €7,182.85, following the last session's upward trend.

nhoa's last close was €4.45, 68.35% below its 52-week high of €14.06.

about nhoa

nhoa s.a. provides energy storage, e-mobility, and ev fastcharging infrastructure related solutions in france. the company offers solar plus storage, utility-scale storage, and industrial microgrids. it also provides charging services and devices for electric and hybrid vehicles. in addition, the company offers power house, and hybrid house; and hyess, a technology platform for the transformation of renewables into sustainable grids, as well as atlante, an estation that provides fast charging solution. nhoa s.a. is based in paris, france.

earnings per share

as for profitability, nhoa has a trailing twelve months eps of €-1.51.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -58.43%.

yearly top and bottom value

nhoa's stock is valued at €4.46 at 11:06 est, way under its 52-week high of €14.06 and way above its 52-week low of €3.15.

revenue growth

year-on-year quarterly revenue growth grew by 262.7%, now sitting on 165.69m for the twelve trailing months.

volume

today's last reported volume for nhoa is 1122 which is 25.08% below its average volume of 20551.

more news about nhoa (nhoa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com